Transcode Therapeutics, Inc. — Form 10-Q
Filed August 14, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 5/100
What the filing says
Philippe P. Calais (CEO) and Thomas A. Fitzgerald (CFO) issued standard Sarbanes-Oxley certifications on August 14, 2026 for the Q2 2026 10-Q ended June 30, 2026. Both officers certified that disclosure controls and internal financial reporting controls are effective, financial statements fairly present the company's condition, and no material weaknesses or fraud were identified. No specific operational, financial, or transactional changes are disclosed in these certification exhibits.
Why this rating
Routine SOX 302/906 certifications; boilerplate filing requirement with no disclosed material events, changes, or transactions. Standard periodic disclosure.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.